| Product Name |
Recombinant Human PLA2G2D / Phospholipase A2 IID Protein |
| Product Overview |
This recombinant human PLA2G2D / Phospholipase A2 IID protein includes amino acids 1-145aa of the target gene is expressed in HEK293 Cells.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization. |
| Target Uniprot Id |
Q9UNK4 |
| Recommended Name |
Group IID secretory phospholipase A2 |
| Gene Name |
PLA2G2D |
| Synonyms |
PLA2IID;sPLA2-IID;sPLA2S;SPLASH |
| Species |
Human |
| Predicted Molecular Mass |
41.5 kDa |
| Expression System |
Mammalian Cell |
| Expression Range |
1-145aa |
| Tag |
C-Fc |
| Purity |
>95% |
| Formulation |
Lyophilized |
| Buffer |
Phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose |
| Storage Condition |
1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Reconstitution Instruction |
Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Applications |
Positive Control; Immunogen; SDS-PAGE; WB |
| Research Area |
Metabolism |
| Target Function |
Secretory calcium-dependent phospholipase A2 that primarily targets extracellular lipids, exerting anti-inflammatory and immunosuppressive functions. Hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) with preference for phosphatidylethanolamines and phosphatidylglycerols over phosphatidylcholines. In draining lymph nodes, selectively hydrolyzes diacyl and alkenyl forms of phosphatidylethanolamines, releasing omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoate and docosahexaenoate that are precursors of the anti-inflammatory lipid mediators, resolvins. During the resolution phase of acute inflammation drives docosahexaenoate-derived resolvin D1 synthesis, which suppresses dendritic cell activation and T-helper 1 immune response. May act in an autocrine and paracrine manner. Via a mechanism independent of its catalytic activity, promotes differentiation of regulatory T cells (Tregs) and participates in the maintenance of immune tolerance. May contribute to lipid remodeling of cellular membranes and generation of lipid mediators involved in pathogen clearance. Displays bactericidal activity against Gram-positive bacteria by directly hydrolyzing phospholipids of the bacterial membrane. |
| Subcellular Location |
Secreted. |
| Protein Family |
Phospholipase A2 family |
| Tissue Specificity |
Highly expressed in pancreas and spleen and less abundantly in colon, thymus, placenta, small intestine, and prostate. |
